These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15093587)

  • 1. Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
    Mouridsen HT; Chaudri-Ross HA
    Eur J Cancer; 2004 May; 40(7):1095-6; author reply 1097. PubMed ID: 15093587
    [No Abstract]   [Full Text] [Related]  

  • 2. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
    Nabholtz JM; Bonneterre J; Buzdar A; Robertson JF; Thürlimann B
    Eur J Cancer; 2003 Aug; 39(12):1684-9. PubMed ID: 12888362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
    Vergote I; Bonneterre J; Thürlimann B; Robertson J; Krzakowski M; Mauriac L; Koralewski L; Webster A; Steinberg M; von Euler M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S84-5. PubMed ID: 11056332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Costa SD; Kaufmann M
    J Clin Oncol; 2001 May; 19(9):2580; author reply 2580-2. PubMed ID: 11331346
    [No Abstract]   [Full Text] [Related]  

  • 7. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Tonkin K
    J Clin Oncol; 2001 May; 19(9):2579-80; author reply 2580-2. PubMed ID: 11331344
    [No Abstract]   [Full Text] [Related]  

  • 8. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Panasci LC
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
    [No Abstract]   [Full Text] [Related]  

  • 9. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Bagley CM; Rowbotham RK
    J Clin Oncol; 2001 May; 19(9):2578-9; author reply 2580-2. PubMed ID: 11331342
    [No Abstract]   [Full Text] [Related]  

  • 10. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Copur MS; Ledakis P; Bolton M; Norvell M; Muhvic J
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331343
    [No Abstract]   [Full Text] [Related]  

  • 11. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
    Nabholtz JM; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
    J Clin Oncol; 2000 Nov; 18(22):3758-67. PubMed ID: 11078488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 13. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
    Bonneterre J; Thürlimann B; Robertson JF; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
    J Clin Oncol; 2000 Nov; 18(22):3748-57. PubMed ID: 11078487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
    J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior efficacy of letrozole versus tamoxifen as first-line therapy.
    Buzdar AU
    J Clin Oncol; 2002 Feb; 20(3):876-8. PubMed ID: 11821477
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
    J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
    Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
    Buzdar AU
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.